RxDoctor Payments Data

Andrew Pundy, MD

Psychiatry · Chicago, ILNPI 1033199336

Payments from drug & device makers

$1,562in general payments, 2019–2025

Across 31 payments — averaging $50.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$495
  • Otsuka America Pharmaceutical, Inc.$343
  • AbbVie$264
  • Idorsia Pharmaceuticals US Inc$124
  • Alkermes, Inc.$120
  • Johnson & Johnson$81
  • plus $136 from 5 others

What the payments were for

  • Food & beverage$1,27381%
  • Education$28919%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,562 in reported general payments places this provider in the 75th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$78,998
Medicare patients
155
Services billed
1,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate24$185,022
Invega SustennaPaliperidone Palmitate49$147,692
Austedo XrDeutetrabenazine13$61,734
VraylarCariprazine Hcl29$55,480
Lurasidone Hcl34$24,996
Aripiprazole153$6,561
Paliperidone ErPaliperidone19$5,095
Bupropion XlBupropion Hcl192$4,020
Divalproex Sodium ErDivalproex Sodium72$3,669
Duloxetine Hcl184$3,266
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine99$3,064
Clonazepam255$2,848
Clozapine97$2,781
Ziprasidone Hcl43$2,552
Olanzapine127$2,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$19$185,02224 claims
Johnson & JohnsonInvega Sustenna$81$147,69249 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$495$61,73413 claims
AbbVieVraylar$264$55,48029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →